2015-28846. Gastroenterology and Urology Devices Panel of the Medical Devices Advisory Committee; Amendment of Notice
-
Start Preamble
AGENCY:
Food and Drug Administration, HHS.
ACTION:
Notice.
SUMMARY:
The Food and Drug Administration (FDA) is canceling the November 18, 2015, session and postponing the November 19, 2015, session of the Gastroenterology and Urology Devices Panel meeting. The meeting was announced in the Federal Register of October 7, 2015 (80 FR 60686). The November 19, 2015, session has been postponed due to the cancellation of the November 18, 2015, meeting. Future meeting dates will be announced in the Federal Register.
Start Further InfoFOR FURTHER INFORMATION CONTACT:
Patricio Garcia, Center for Devices and Radiological Health, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 66, Rm. 1535, Silver Spring MD 20993-0002, patricio.garcia@fda.hhs.gov, 301-796-6875, or FDA Advisory Committee Information Line, 1-800-741-8138 (301-443-0572 in the Washington DC area), and follow the prompts to the desired center or product area. Please call the Information Line for up-to-date information on this meeting.
Start SignatureDated: November 9, 2015.
Leslie Kux,
Associate Commissioner for Policy.
[FR Doc. 2015-28846 Filed 11-13-15; 8:45 am]
BILLING CODE 4164-01-P
Document Information
- Published:
- 11/16/2015
- Department:
- Food and Drug Administration
- Entry Type:
- Notice
- Action:
- Notice.
- Document Number:
- 2015-28846
- Pages:
- 70825-70825 (1 pages)
- Docket Numbers:
- Docket No. FDA-2015-N-0001
- PDF File:
- 2015-28846.pdf
- Supporting Documents:
- » Attachment 3 Neurovascular Quality Initiative List of Devices re: Comment from M2S, Inc.
- » Attachment 2 Neurovascular Quality initiative 2015 Procedure Inclusion/Exclusion Criteria re: Comment from M2S, Inc.
- » Transcript of the March 30-31, 2015 Gastroenterology Regulatory Endpoints and the Advancement of Therapeutics (GREAT) III Workshop on Inflammatory Bowel Disease, Day 2
- » Transcript of the March 30-31, 2015 Gastroenterology Regulatory Endpoints and the Advancement of Therapeutics (GREAT) III Workshop on Inflammatory Bowel Disease, Day 1